|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Luke Miels
|
|||
|
b)
|
Position/status
|
Chief Executive Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2026
on Ordinary Shares held in the Company’s Deferred Annual
Bonus Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.3550
|
756
|
|
||
|
|
£17.3550
|
379
|
|
||
|
|
£17.3550
|
278
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,413
£17.3550
|
|||
|
e)
|
Date
of the transaction
|
2026-10-12
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Julie Brown
|
|||
|
b)
|
Position/status
|
Chief Financial Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2026
on Ordinary Shares held in the Company’s Deferred Annual
Bonus Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.3550
|
607
|
|
||
|
|
£17.3550
|
707
|
|
||
|
|
£17.3550
|
549
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,863
£17.3550
|
|||
|
e)
|
Date
of the transaction
|
2026-10-12
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
James Ford
|
|||
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2026
on Ordinary Shares held in the Company’s Deferred Annual
Bonus Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.3550
|
406
|
|
||
|
|
£17.3550
|
246
|
|
||
|
|
£17.3550
|
131
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
783
£17.3550
|
|||
|
e)
|
Date
of the transaction
|
2026-10-12
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Shobie Ramakrishnan
|
|||
|
b)
|
Position/status
|
Chief Digital and Technology Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares (‘ADS’)
ISIN: US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADS following the re-investment of
dividends paid to shareholders on 8 October 2026 on ADS held in the
Company’s Deferred Annual Bonus Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$46.5400
|
188
|
|
||
|
|
$46.5400
|
113
|
|
||
|
|
$46.5400
|
63
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
364
$46.5400
|
|||
|
e)
|
Date
of the transaction
|
2026-10-12
|
|||
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
David Redfern
|
|||
|
b)
|
Position/status
|
President, Corporate Development
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2026
on Ordinary Shares held in the Company’s Deferred Annual
Bonus Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.3550
|
481
|
|
||
|
|
£17.3550
|
219
|
|
||
|
|
£17.3550
|
194
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
894
£17.3550
|
|||
|
e)
|
Date
of the transaction
|
2026-10-12
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Regis Simard
|
|||
|
b)
|
Position/status
|
President, Global Supply Chain
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2026
on Ordinary Shares held in the Company’s Deferred Annual
Bonus Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.3550
|
579
|
|
||
|
|
£17.3550
|
321
|
|
||
|
|
£17.3550
|
203
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,103
£17.3550
|
|||
|
e)
|
Date
of the transaction
|
2026-10-12
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Philip Thomson
|
|||
|
b)
|
Position/status
|
President, Global Affairs
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2026
on Ordinary Shares held in the Company’s Deferred Annual
Bonus Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.3550
|
324
|
|
||
|
|
£17.3550
|
195
|
|
||
|
|
£17.3550
|
141
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
660
£17.3550
|
|||
|
e)
|
Date
of the transaction
|
2026-10-12
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Deborah Waterhouse
|
|||
|
b)
|
Position/status
|
CEO, ViiV Healthcare and President, Global Health, GSK
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2026
on Ordinary Shares held in the Company’s Deferred Annual
Bonus Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.3550
|
501
|
|
||
|
|
£17.3550
|
302
|
|
||
|
|
£17.3550
|
184
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
987
£17.3550
|
|||
|
e)
|
Date
of the transaction
|
2026-10-12
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Tony Wood
|
|||
|
b)
|
Position/status
|
Chief Scientific Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2026
on Ordinary Shares held in the Company’s Deferred Annual
Bonus Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.3550
|
618
|
|
||
|
|
£17.3550
|
281
|
|
||
|
|
£17.3550
|
258
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,157
£17.3550
|
|||
|
e)
|
Date
of the transaction
|
2026-10-12
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Maya Martinez-Davis
|
|||
|
b)
|
Position/status
|
President, US
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADS')
ISIN: US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of ADS following the re-investment of dividends paid to
shareholders on 8 October 2026
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$46.5400
|
179.308
|
|
||
|
|
|||||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-12
|
|||
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Julie Brown
|
|||
|
b)
|
Position/status
|
Chief Financial Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on Ordinary Shares
held in the Company’s Performance Share Plan subject to a
2-year holding period
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.3550
|
2,409.639
|
|
||
|
|
|
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-12
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: October
14, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|